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Partially fueled by the human immunodeﬁciency
virus (HIV) pandemic, tuberculosis is the second-
leading cause of infectious diseases–associated mor-
tality globally and the leading cause of death among
those infected with HIV. In 2010, there were an esti-
mated 8.8 million incident cases of tuberculosis and
approximately 1.5 million deaths attributed to tubercu-
losis. Increased public heath efforts have been effective
in decreasing the overall prevalence and mortality
associated with this disease, but declines in incidence
rates have been outpaced by global population growth,
such that absolute incidence rates have not declined
as fast as previously expected [1]. Commensurate with
increased public recognition of the importance of tuber-
culosis to global health in the mid-1990s, biomedical
research for tuberculosis has increased both in the
United States and internationally. Although tools to
conduct modern biomedical research involving tubercu-
losishave only been available for a little over a decade,
this research has resulted in several successes, including
promising new vaccines to protect against tuberculo-
sis in the highest-risk populations, diagnostic candi-
dates to improve the accuracy and speed of diagnosing
all forms of tuberculosis, and new drug candidates with
the potential for improved treatment and chemopreven-
tion for drug-sensitive and drug-resistant tuberculosis.
Despite these successes, many questions remain in
all aspects of tuberculosis research, ranging from
fundamental pathogenesis to programmatic implemen-
tation, and they are complicated by the complexity
of the disease and its chronic nature. Compared with
other infections, Mycobacterium tuberculosis infection
does not elicit clinically relevant disease in the majority
of subjects, and many who are infected carry asymp-
tomatic, paucibacillary disease for decades. This com-
plicates the deﬁnition and evaluation of early infection
events and initial host responses and the character-
ization of infecting bacillary populations. The clini-
cal deﬁnition of latent infection is limited to positive
responses to injection of puriﬁed mycobacterial compo-
nents (ie, the tuberculosis skin test) or to T-cell–recall
responses measured through the production of inter-
feron c; unlike viral infections, latent tuberculous in-
fections cannot be identiﬁed on the basis of stable
antibody titers. Progression to active disease is not
a clear unidirectional process and is prolonged, and
many affected persons appear to be able to clear the in-
fection, whereas others progress to active disease. The
spectrum of active tuberculosis is complex. Although
adult pulmonary tuberculosis is considered of greatest
relevance for public health, extrapulmonary disease
occurs in a signiﬁcant portion of subjects, and pedi-
atric manifestations of tuberculosis may be mistaken
for other pulmonary infections and are difﬁcult to diag-
nose. Treatment of active disease is complicated by the
fact that the current standard of care involves combina-
tions of drugs whose administration is sequenced on
the basis of the clearance of mycobacteria from sputum
and that, unlike most other antibacterial treatments,
have to be administered for a minimum of 6 months
to elicit a stable cure. Hypotheses exist that explain
the need for such prolonged therapy, but they are
difﬁcult to test experimentally because initial treat-
ment of tuberculosis eliminates bacteria from spu-
tum and thus limits options for studying bacterial
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culosis, patients do not become immune to reinfection at a later
time. Thus, a clear deﬁnition of the markers of immune pro-
tection is dependent on successful trials of new vaccines or
has to be derived from data for persons who were infected
but did not progress to active disease. However, both criteria
are complicated by the limitations listed above.
Comprehensive reviews of research priorities that have
been deﬁned on the basis of the unique nature of tubercu-
losis and the associated scientiﬁc/technical limitations of
studying the disease have been addressed elsewhere [2–5],
but several issues merit further exploration.
FUNDAMENTAL RESEARCH
An understanding of the differences and commonalities of
tuberculosis among high-burden countries is critical for
a better understanding of the global tuberculosis epidemic,
the natural history of the disease, and, ultimately, the de-
velopment of appropriate scientiﬁc approaches for discovery
and development of drugs, vaccines, and diagnostics appli-
cable in these settings (Ibrahim Abubakar, et al, ‘‘Drug
resistant tuberculosisdcurrent dilemmas and unanswered
questions,’’ this Journal of Infectious Diseases supplement).
In particular, the evaluation of the natural history of tuber-
culosis in the context of coinfections, comorbidities, risk
behaviors, and other factors that are prevalent in these
countries is critical to understanding tuberculosis in its
natural setting. The complex interplay between pathogen
and host immunity and the contribution of strain genetics
to host immune response, transmission, pathogenicity, and
acquisition of resistance need to be better understood to
develop interventions that are either targeted to a speciﬁc
setting or applicable worldwide (Susanna Brighenti and Jan
Andersson, ‘‘Local immune responses in human tuberculosis:
learning from the site of infection, this Journal supplement;
Rebecca Axelsson-Robertson et al, ‘‘The immunological foot-
print of M. tuberculosis T-cell epitope recognition,’’ this Journal
supplement). In particular, our understanding of transmission
and of the nature and/or number of sequential exposure
events required for infection and eventual latency or active
disease are limited and complicate our characterization of
the associated early host and pathogen factors. Application
of state-of-the-art genomics, systems biology, and creative
bioinformatics analyses promise to shed light on the com-
plexity of these interactions. With further development and
reﬁnement, molecular investigations of the genetic factors
underlying virulence, pathogenicity, and drug resistance in
M. tuberculosis may provide the backbone for the design of
drugs, vaccines, and diagnostics.
Epidemiologic data are essential to properly inform the
development of implementation research agendas to ensure
that investments inproduct development are properly paired
with in-country science, to facilitate clinical trials and
product roll out (Frank Cobelens, et al, ‘‘Which new diag-
nostics for tuberculosis, and when?’’ this Journal supple-
ment). Although implementation research has traditionally
been regarded separately from basic and clinical research, the
HIV and tuberculosis epidemics exemplify the importance
of addressing the ultimate goaldto use new research devel-
opments to deliver better care and end both epidemics.
Prescient consideration of operational issues promises faster
translation of scientiﬁc discoveries and new technologies
into clinical use. Optimally, clinical development and imple-
mentation research are done in parallel to decrease delay in
programmatic implementation. For example, implementation
research done now to translate current childhood immuni-
zation programs into effective programs for adolescents and
adults will be critical to the rapid roll out of licensed tuber-
culosis and HIV vaccines in the future. The recognition that
fundamental research is a critical component of the global
ﬁght against tuberculosis and the prerequisite for development
of new healthcare interventions for tuberculosis has recently
been highlighted by inclusion, for the ﬁrst time, of a chapter
on research and development in the World Health Organ-
ization’s annual report on global tuberculosis control [1]a n d
by summarization of these activities in the research roadmap
of the Stop TB Partnership’s TB Research Movement [5].
PREVENTION
An effective vaccine may offer the best hope to eventually
eradicate tuberculosis. The only licensed tuberculosis vac-
cine, BCG, is the most widely used vaccine globally. More
than 100 million doses of BCG vaccine are given annually to
protect infants in high-burden countries from tuberculosis,
including often fatal forms of extrapulmonary tuberculosis.
The BCG vaccine’s efﬁcacy in protecting against adult pul-
monary disease greatly varies globally, and it is not consid-
ered a reliable tool for tuberculosis control. The current
pipeline for tuberculosis vaccines includes a diverse collec-
tion of delivery platforms and adjuvants, live attenuated
vaccines, and prime-boost combinations [6, 7].
Despite increased efforts in tuberculosis vaccine research,
large gaps exist in our understanding of tuberculosis. Tuber-
culous mycobacteria are able to evade host immune responses,
and factors associated with establishment of immune memory
after infection/disease are unclear (Rebecca Axelsson-Robertson
et al, ‘‘The immunological footprint of M. tuberculosis T-cell
epitope recognition,’’ this Journal supplement). This, coupled
with the prolonged time between infection and disease mani-
festation and priming of cross-reactive immune responses by
exposure to environmental mycobacteria and/or BCG vaccine,
complicates assessment of the status of tuberculous infection.
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prevention of infection, but include vaccines to prevent dis-
ease activation and therapeutic vaccines as adjuncts to che-
mopreventive therapy for persons already infected.
Additionally, recent evidence [8]s u g g e s t i n gt h ee f ﬁ c a c yo f
short-duration, combination, chemoprevention strategies is
an important development that deserves further consider-
ation, especially in HIV-infected persons and other immu-
nocompromised populations. In addition to evaluation of
new combinations/approaches to further increase efﬁcacy
and shorten required treatment duration, implementation
research on the feasibility of chemoprevention strategies and
their potential impact on treatment programs and local tuber-
culosis epidemiology are also needed. Furthermore, treat-
ment of individuals (both adults and children) exposed to
drug-resistant tuberculosis represents an important knowl-
edge gap that requires evaluation.
The current tuberculosis prevention portfolio is complex
and diverse. To address the absence of surrogate markers of
efﬁcacy, immune-response assays are being developed as
vaccines are tested in humans. Current clinical trials offer an
opportunity to search for useful correlates of protection.
Additionally, the availability of better epidemiologic data
would help inform trial design in the setting of changing
demographic data, increasing coverage with antiretroviral
therapy, and aging among the populations at highest risk.
TUBERCULOSIS DIAGNOSIS
Improving the diagnosis of latent tuberculosis infection,
identifying persons most likely to advance to active disease,
rapidly detecting pulmonary and nonpulmonary tubercu-
losis by use of nonsputum samples, identifying persons most
likely to relapse after treatment, and developing affordable,
rapid methods for identifying drug resistance are critically
needed advances. These advances will require a detailed un-
derstanding of the dynamics and molecular/immunologic
characteristics of the disease in humans and the identiﬁca-
tion of biomarkers (host and microbial) indicative of the
various stages of disease and treatment response. The com-
plexities involved in this research portend that signiﬁcant
advances will not be easy, but the potential impact of
such biomarkers is compelling. Besides the obvious clinical
usefulness (eg, allowing prioritization and/or improved
prediction of individuals requiring chemopreventive treat-
ment), these tests could be used as surrogate end points to
improve the efﬁciency of early phase evaluations and to
greatly reduce the prolonged follow-up period currently
required for late-phase drug and vaccine clinical trials
[9, 10].
Nucleic acid ampliﬁcation technologies coupled with mole-
cular detection systems represent a very important modern
achievement in the ﬁeld of tuberculosis diagnostics. Line
probe assays and the Xpert MTB/RIF test provide laborato-
ries with the ability to accurately diagnose tuberculosis
and detect multidrug-resistant tuberculosis in a fraction of
the time required by traditional culture-based methods. The
,2-hour diagnosis time afforded by the Xpert MTB/RIF
assay for detection of both tuberculous disease and rifampin
resistance has the potential to signiﬁcantly impact the care of
patients with tuberculosis and, particularly, those with drug-
resistant tuberculosis, provided the technology continues to be
made available to laboratories in high-burden countries (Ruth
McNerney et al, ‘‘Tuberculosis diagnostics and biomarkers,’’
this Journal supplement). Despite these successes, effective
tuberculosis diagnosis and detection of drug resistance still
remain elusive in many regions of the world, especially in
pediatric and HIV-infected populations. Research is needed
to determine whether these assays will also be effective for
accurate diagnosis of extrapulmonary tuberculosis and
childhood tuberculosis (Stephen Graham et al, ‘‘Evaluation
of tuberculosis diagnostics in children: 1. Proposed clinical
deﬁnitions,’’ this Journal supplement; Luis Cuevas et al,
‘‘Evaluation of tuberculosis diagnostics in children: 2.
Methodological issues,’’ this Journal supplement). In addi-
tion to the need to strategically ramp up implementation of
new assays, true point-of-care diagnostics that can quickly
and accurately diagnose tuberculosis without electricity and
technical expertise at low costs are needed for ﬁrst-line
clinics in resource-limited settings (M. L. Schito et al,
‘‘Opportunities and challenges for cost-effective imple-
mentation of new point of care diagnostics for HIV and
Tuberculosis,’’ this Journal supplement). Although much
work is ongoing, combination strategies (multianalyte and
multiplatform) may be required to overcome the weaknesses
of individual diagnostics and to efﬁciently address detection
of coinfections, such as HIV infection and hepatitis B and C
virus infections.
Closely tied to the development of new combination
therapies for tuberculosis is the need to rapidly and accu-
rately detect drug resistance at the patient level and catalog
existing drug resistance patterns at the population level.
While the clinical deﬁnition of multidrug-resistant and exten-
sively drug-resistant tuberculosis covers resistance to isoniazid,
rifampin, ﬂuoroquinolones, and the injectable drugs, drug
resistance testing for other ﬁrst- and second-line agents,
against which clinical resistance may be signiﬁcant, is not
commonly included in national surveys. For pyrazinamide,
difﬁculties associated with culture-based assessment of re-
sistance present challenges for patient care, public health
monitoring, and drug development. As new drugs are made
available for general use, strategies to prevent rapid de-
velopment of resistance to additional drugs in effective
multidrug regimens will be important. Assays for molecular
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need [11]; however, data are needed on the clinical useful-
ness of genotypic resistance proﬁles to determine optimal
drug regimens for clinical care. Further determination of the
full spectrum of clinically relevant drug resistance mutations
is also critical (P. Nahid et al, ‘‘Clinical research and de-
velopment of tuberculosis diagnostics,’’ Journal supplement,
this issue).
Besides diagnostic platforms intended for clinical care,
tests with speciﬁc usefulness for drug-development studies
are also needed. Studies correlating high-resolution com-
puted tomography (CT) and positron emission tomography
(PET)/CT to treatment outcomes indicate that imaging
modalities may have the potential to serve as early surrogate
biomarkers in clinical drug combination development (L. Via,
personal communication). Development of improved tracers
with longer half-lives and better speciﬁcity for tuberculous my-
cobacteria is being pursued, and magnetic resonance imaging/
PET may provide further advances. Standardized imaging
protocols, data elements, analysis methods, and optimal
cutoff criteria to deﬁne the degree of treatment response will
need to be developed.
Development of a real-time quantitative ribosomal RNA
assay for sputum analysis also appears to be a promising
technique for measurement of viable bacteria in serial spu-
tum samples, including nonreplicating persistent organisms
[12]. Its application to phase II studies could replace current
culture-based methods and could be more cost effective.
Real-time measurements like this assay and imaging tech-
nologies will greatly facilitate the efﬁciency of clinical drug
development research by facilitating rapid decision making
in phase II adaptive trials (P. Phillips et al, ‘‘Innovative trial
designs are practical solutions for improving the treatment of
tuberculosis,’’ Journal supplement, this issue).
TUBERCULOSIS TREATMENT
New treatment regimens for patients with drug-resistant and
drug-sensitive tuberculosis are urgently needed. The long
duration and poor tolerability of current regimens represent
important challenges to curbing the tuberculosis pandemic.
The global incidence of multidrug-resistant tuberculosis
currently stands at 3.6% of all tuberculosis cases, with sub-
stantially higher rates in certain regions such as eastern
Europe, southern Africa, and central Asia, and in cases of
tuberculosis retreatment as compared with new cases [13].
T h eh i g hr a t eo fd e f a u l ta n dt r e a t m e n tf a i l u r ea s s o c i a t e dw i t h
current tuberculosis regimens under programmatic condi-
tions is a contributing factor to this problem, and new, more
effective, and shorter treatment regimens and other treat-
ment improvement approaches for both drug-sensitive and
drug-resistant tuberculosis are essential.
With a pipeline of new drugs for tuberculosis that is more
robust than ever, the efﬁcient evaluation of individual agents
and combinations will be critical. Advanced planning and
coordinated assessment of treatment combinations is a high
priority to ensure that development of new drug regimens is
based on pharmacological and antimicrobial compatibility
and results in the most efﬁcacious and safe new regimens.
While early-phase studies may give a relatively rapid and
early indication of optimal dose and drug combinations, the
u s eo fd i s e a s er e l a p s ea st h eu l timate end point for clinical
efﬁcacy will require large and prolonged phase III trials to
conﬁrm long-term safety and efﬁcacy. Development of
regimens on the basis of the most appropriate preclinical and
animal model tests and use of adaptive trial designs
(P. Phillips et al, ‘‘Innovative trial designs are practical sol-
utions for improving the treatment of tuberculosis,’’ Journal
supplement, this issue) will facilitate optimal use of limited
clinical trials capacity and provide opportunities for the addi-
tion of nested studies of biomarkers to establish their use for
prediction of clinical treatment response.
Rational design of optimal multidrug regimens will re-
quire consideration of multiple factors beyond clinical efﬁ-
cacy, including drug interaction effects, pharmacokinetics,
toxicity, drug metabolism, and the thresholds for development
of resistance associated with the component drugs. Antitu-
berculous drugs with high barriers to resistance will be im-
portant not only for their therapeutic efﬁcacy, but also for
their ability to protect other drugs in the combination reg-
imen. Sensible drug sequencing/staging strategies to improve
outcomes with current drugs are also needed. These strategies
would capitalize on known mechanisms of action and ac-
tivities against the spectrum of bacterial subpopulations
(from rapid replicators to semidormant organisms) and
minimize antagonistic interactions (eg, between isoniazid
and pyrazinamide). Additionally, with the recognition that
patients with tuberculosis frequently present with coinfections
and comorbidities, compatibility of antituberculous drugs with
drugs to treat comorbid conditions such as heart disease,
diabetes, HIV infection, and other chronic viral infections
must be assessed at the earliest possible stage in clinical
development. Comparative studies are needed because some
current regimens, particularly those to treat multidrug-
resistant and extensively drug-resistant tuberculosis, are
poorly characterized and therefore difﬁcult to use as bench-
marks for improvement of treatment [14]. Further develop-
ment and application of these approaches and concepts to
the pediatric population will be critical.
An understanding of the nature and characteristics of
‘‘persister’’ organisms and dormancy is fundamental to de-
veloping a reasonable strategy for shortening the duration of
current tuberculosis treatment. Although the presence of
a spectrum of actively replicating to nonreplicating persister
S350 d JID 2012:205 (Suppl 2) d Kim et alpopulations in active tuberculosis has been hypothesized for
many years [15, 16] ,t h er o l et h e s eo r g a n i s m sp l a yi na c t i v e
human tuberculosis has not been well characterized. Much
of the related research has been indirect or based on animal
model studies of unproven relevance to tuberculosis in humans.
The recent discovery of resuscitation-promoting factors [17],
if validated, offers potential for evaluating nonreplicating
persister populations in clinical studies. Appropriate in vitro
and in vivo models to elucidate the activity of new drugs
against the full spectrum of mycobacterial populations are
critical to identifying the most-potent sterilizing combina-
tions of drugs to shorten treatment durations.
A short, potent regimen will require antimicrobial effects
against a spectrum of M. tuberculosis populations, and drugs
targeting universal, essential microbial pathways may play
a signiﬁcant role. For instance, disruption of basal energy/
adenosine triphosphate production needed to maintain mem-
brane structural and functional integrity, including proton
motive force, and direct disruption of components of the
mycobacterial cell membrane may offer key points of in-
tervention. New insights into the functions responsible for
the viability of highly stressed cells has been gained from the
recent discovery of a mechanism of action of pyrazinamide, in-
hibition of trans-translation [18].
A new area of research for improving and shortening the
duration of tuberculosis treatment is the combination of
immune-protective mechanisms in conjunction with chemo-
therapy to aid in the prevention of disease activation or to
assist in the rapid eradication of mycobacterial populations
through host immune mechanisms, especially in the setting
of drug-resistant disease (M. Uhlin et al, ‘‘Biological and
adjunct immunotherapies for difﬁcult to treat, drug resistant
tuberculosis,’’ Journal supplement, this issue). Critical to the
success of the combination of deﬁned molecular vaccines
(adjuvanted protein, DNA, or virally vectored) and drug
therapy is the coordination of drug and vaccine research. In
addition, treatment and prevention modalities for tuberculosis
may have to address host and pathogen factors alike to be suc-
cessful.
THE PATH FORWARDdTHE CRITICAL NEED
FOR COORDINATION
T h ei m p o r t a n c eo fe n h a n c e dc o m m u n i c a t i o n ,c o o r d i n a t i o n ,
and, when appropriate, collaboration cannot be overstated.
For example, the implementation of long-term, coordinated
multisite, prospective cohorts in diverse tuberculosis-endemic
countries could serve as a critical building block in future tuber-
culosis research efforts and scientiﬁc strategies geared toward
optimizing tools and approaches in both fundamental and
clinical research. Accelerated translation of fundamental
scientiﬁc discoveries into clinically relevant technologies and
interventions requires increased cooperation across disciplines
and among various research organizations (including those
in tuberculosis-endemic countries), funding agencies, imple-
menting programs, and others that make up the global tuber-
culosis research community. Effective coordination efforts for
tuberculosis diagnostic/biomarker, therapeutic, and vaccine
research are critical at this time. The Stop TB Partnership’s
Working Groups and TB Research Movement are important
foundations for research coordination and collaboration.
Undoubtedly, a wide variety of agreements and coordinating
bodies will be required to realize such a large objective, but
they should all share the fundamental principle of efﬁcient
and timely sharing of information among the participating
organizations. This will facilitate maximum productivity
by coordinating research activities across the continuum
of tuberculosis research and guarding against unnecessary
bureaucratization of working relationships. The common
overall goal is to advance key research objectives rapidly and
cost effectively, while maintaining the highest standards of
scientiﬁc rigor.
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